Jay Yang, MD, discusses the current treatment landscape of mantle cell lymphoma.
Jay Yang, MD, oncologist, Malignant Hematology, the Karmanos Cancer Institute, discusses the current treatment landscape of mantle cell lymphoma (MCL).
Compared with other types of lymphoma, MCL is unique in the sense that it does not have a true standard of care, Yang says. This is partially due to the heterogeneity of MCL, since the presentation of the disease, its prognosis, and therapies can all vary, leading to a range of long-term outcomes, Yang explains.
Although some patients with MCL have such indolent disease that they can be observed initially without any therapy, most patients with MCL will need treatment, Yang concludes.